Eisai and TorreyPines Therapeutics Research Treatment for Alzheimer's Disease
TorreyPines Therapeutics, Inc. and Eisai Co., Ltd. announced the signing of a research agreement involving Alzheimer's disease drug discovery.
The goal of the research performed by TorreyPines Therapeutics is to discover novel Alzheimer's disease modifying agents based on the study of the mechanism of the disease's pathogenesis. Under this agreement, Eisai will have exclusive rights of first negotiation and refusal for validated compounds discovered through the research. Eisai and TorreyPines Therapeutics may enter into drug development agreements involving certain validated compounds that meet a pre-determined set of criteria defined in the current agreement.
"We are pleased to work with Eisai once again in the field of Alzheimer's disease therapeutics," said Neil Kurtz, MD, President and CEO of Torrey Pines Therapeutics. "We look forward to advancing this program with Eisai's support, as well as continuing to work with them on our first research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer's disease"
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.